DEVICE DEVELOPMENT AND SUPPLY AGREEMENTDevice Development and Supply Agreement • March 20th, 2023 • Liquidia Corp • Pharmaceutical preparations
This Device Development and Supply Agreement (“Agreement”) is made this 1st day of December, 2022 by and among Mainbridge Health Partners, LLC, with its principal place of business at 30399 North Chardon Lane; Grayslake IL 60030, (“Mainbridge”), Liquidia PAH, LLC, with its principal place of business at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (“Liquidia”) and Sandoz Inc., with its principal place of business at 100 College Road West, Princeton, NJ, 08540 (“Sandoz” and, collectively with Mainbridge and Liquidia, the “Parties” and each a “Party”).
THIRD AMENDMENT TO PROMOTION AGREEMENTPromotion Agreement • March 20th, 2023 • Liquidia Corp • Pharmaceutical preparations • New York
This Third Amendment to Promotion Agreement (this “Third Amendment”), is entered into as of November 18, 2022 (the “Third Amendment Effective Date”) by and between Sandoz Inc. (“Sandoz”) and Liquidia PAH, LLC, formerly known as RareGen, LLC (“RareGen”).
REVENUE INTEREST FINANCING AGREEMENT by and among LIQUIDIA TECHNOLOGIES, INC., as the Company, HEALTHCARE ROYALTY PARTNERS IV, L.P., as the Investor and HCR COLLATERAL MANAGEMENT, LLC, as the Investor Representative Dated January 9, 2023Revenue Interest Financing Agreement • March 20th, 2023 • Liquidia Corp • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of January 9, 2023 (the “Effective Date”), is by and among LIQUIDIA TECHNOLOGIES, INC., a Delaware corporation (the “Company”), HEALTHCARE ROYALTY PARTNERS IV, L.P., a Delaware limited partnership (the “Investor”), and HCR COLLATERAL MANAGEMENT, LLC, a Delaware limited liability company (the “Investor Representative”), solely in its capacity as agent for, and representative of, the Investor. Each of the Company and the Investor are referred to in this Agreement as a “Party” and, collectively, as the “Parties”.
